Press Releases April 29, 2026 04:15 PM

Palomar Holdings, Inc. Announces First Quarter 2026 Financial Results Release Date and Conference Call

Palomar Holdings to release Q1 2026 financial results with a scheduled conference call in early May

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
PLMR

Palomar Holdings, Inc., a specialty insurer, announced the date for its first quarter 2026 earnings release on May 6, 2026, followed by a conference call on May 7, 2026. The company operates in various insurance lines including earthquake, inland marine, casualty, crop, and surety & credit with subsidiaries holding A.M. Best ratings from A- to A.

Palomar Holdings, Inc. Announces First Quarter 2026 Financial Results Release Date and Conference Call
PLMR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Scheduled release of Q1 2026 financial results and conference call indicates transparency and ongoing communication with investors.
  • Palomar Holdings operates across multiple specialty insurance sectors, including earthquake, inland marine, casualty, crop, and surety & credit.
  • The company’s subsidiaries carry strong A.M. Best financial strength ratings, signaling financial stability.

LA JOLLA, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Palomar Holdings, Inc. (NASDAQ: PLMR) (the “Company”) today announced that it will release its first quarter 2026 results after the market close on Wednesday, May 6, 2026, and will host a conference call at 12:00 p.m. (Eastern Time) the following day, Thursday, May 7, 2026.

The conference call can be accessed live by dialing 1-877-423-9813 or for international callers, 1-201-689-8573, and requesting to be joined to the Palomar First Quarter 2026 Earnings Conference Call. A replay will be available starting at 4:00 p.m. (Eastern Time) on May 7, 2026, and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the replay is 13759747. The replay will be available until 11:59 p.m. (Eastern Time) on May 14, 2026.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the investor relations section of the Company's website at https://ir.palomarspecialty.com/. The online replay will remain available for a limited time beginning immediately following the call.

About Palomar Holdings, Inc.

Palomar Holdings, Inc. is the holding company of subsidiaries Palomar Specialty Insurance Company (“PSIC”), Palomar Specialty Reinsurance Company Bermuda Ltd. (“PSRE”), Palomar Insurance Agency, Inc., Palomar Excess and Surplus Insurance Company (“PESIC”), Palomar Underwriters Exchange Organization, Inc. (“PUEO”), First Indemnity of America Insurance Co. (“FIA”), Palomar Crop Insurance Services, Inc. (“PCIS”), and Palomar Casualty and Surety Company (“PCSC”), formerly known as The Gray Casualty & Surety Company. Palomar’s consolidated results also include Laulima Exchange (“Laulima”), a variable interest entity for which the Company is the primary beneficiary. Palomar is an innovative specialty insurer serving residential and commercial clients in five product categories: Earthquake, Inland Marine and Property, Casualty, Crop, and Surety & Credit. Palomar’s insurance subsidiaries, PSIC, PSRE, PESIC, and FIA have a financial strength rating of “A” (Excellent) from A.M. Best and PCSC has a financial strength rating of “A-” (Excellent) from A.M. Best.

To learn more, visit PLMR.com

Follow Palomar on LinkedIn: @PLMRInsurance

Contact
Media Inquiries
Lindsay Conner
1-551-206-6217
lconner@plmr.com

Investor Relations
Jamie Lillis
1-203-428-3223
investors@plmr.com   
Source: Palomar Holdings, Inc.


Risks

  • Earnings results could fall short of investor expectations, impacting stock price negatively.
  • Market conditions or claims experience in specialty insurance sectors could affect financial performance.
  • The company’s diversified specialty insurance products could face regulatory or environmental risks affecting underwriting outcomes.

More from Press Releases

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026 Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism Jun 13, 2026 Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026